Tuzi A, Lombardi D, Crivellari D, Militello L, Perin T, La Grassa M, et al. Epirubicin and Docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: results from two successive phase II studies. Radiol Oncol [Internet]. 2013 Apr. 2 [cited 2026 Sep. 4];47(1). Available from: https://radioloncol.com/index.php/ro/article/view/728